|[March 29, 2014]
AccessClosure Launches the Next-Generation Mynx Ace™ Vascular Closure Device at Annual ACC Meeting
SANTA CLARA, Calif. --(Business Wire)--
Inc., the market leader in extravascular care technology, has
commercially launched its Mynx Ace Vascular Closure Device, a safe and
secure vascular closure product that provides consistent results with a
new, easy-to-use deployment system1 to seal femoral artery
access sites. The device joins the pioneering line of Mynx extravascular
products that help care teams reduce time to hemostasis and ambulation
in patients who have undergone diagnostic or interventional endovascular
procedures. The commercial launch was announced as part of the annual
meeting of the American College of Cardiology.
Mynx Ace Vascular Closure Device (AccessClosure Inc., Santa Clara, Calif.)
"We are proud of the advantages Mynx Ace offers to femoral closure,"
said Gregory D. Casciaro, presidnt and CEO of AccessClosure Inc. "Our
continual drive toward innovations that provide physicians with
outstanding products to improve patient care has allowed us to develop a
closure device that provides consistent results, while continuing to
offer the safety and security that has become synonymous with the Mynx
Mynx closure devices are designed for patient comfort by providing
gentle vascular closure without the use of cinching, sutures, or metal
implants to enhance patient satisfaction and keep physicians on the
leading edge of patient care.2 With Mynx Ace, physicians can
consistently close femoral artery access sites through a simple,
three-step deployment system. The Mynx Ace system uses AccessClosure's
proprietary Grip Technology™, a major advancement in sealant technology.
Grip Technology employs an extravascular sealant that actively adheres
to the artery for safe and secure mechanical closure and dissolves
within 30 days, leaving nothing behind in the healed vessel.
"After completing over 50 cases with Mynx Ace, I have found the system
provides consistent results while offering the safety, security and
patient-friendly advancements I have come to trust in Mynx products,"
said Rajesh Dave, MD, a cardiologist from Holy Spirit Hospital in Camp
Hill, PA. "The advancements have made Mynx Ace a preferred closure
device in my practice."
Mynx Ace can be used with patients who have undergone diagnostic or
interventional endovascular procedures utilizing a 5F, 6F or 7F
procedural sheath. It is estimated that more than 2.1 million of these
procedures are conducted each year in the United States.
Founded in 2002, AccessClosure, Inc. is a privately held medical device
company pioneering innovative, patient-friendly products designed to
address complex challenges in the cardiovascular and peripheral vascular
markets. For more information, visit our website at www.accessclosure.com.
1. As compared to earlier generations of Mynx closure devices. Test
data on file at AccessClosure.
2. Fargen KM, Hoh Bl, Mocco J. J
NeuroIntervent Surg (2011).
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140329005004/en/
[ Back To TMCnet.com's Homepage ]